278 related articles for article (PubMed ID: 15449974)
21. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
22. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Wade WE; Spruill WJ; Leslie RB
Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
[TBL] [Abstract][Full Text] [Related]
23. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
Turpie AG
Int J Clin Pract; 2004 May; 58(5):483-93. PubMed ID: 15206506
[TBL] [Abstract][Full Text] [Related]
24. Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
Lobo BL
Pharmacotherapy; 2004 Jul; 24(7 Pt 2):66S-72S. PubMed ID: 15317401
[TBL] [Abstract][Full Text] [Related]
25. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
26. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Turpie AG
Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
[TBL] [Abstract][Full Text] [Related]
28. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Olsen J; Gundgaard J; Borris LC
Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
[No Abstract] [Full Text] [Related]
29. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of enoxaparin versus aspirin in the prevention of venous thromboembolism after total hip or knee arthroplasty: an analysis from the CRISTAL cluster-randomized trial.
CRISTAL Economic Analysis Study Group
Bone Joint J; 2024 Jun; 106-B(6):589-595. PubMed ID: 38821513
[TBL] [Abstract][Full Text] [Related]
31. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty.
Spruill WJ; Wade WE; Leslie RB
Am J Ther; 2004; 11(1):3-8. PubMed ID: 14704589
[TBL] [Abstract][Full Text] [Related]
32. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.
Lundkvist J; Bergqvist D; Jönsson B
Eur J Health Econ; 2007 Dec; 8(4):313-23. PubMed ID: 17225129
[TBL] [Abstract][Full Text] [Related]
35. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
36. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Doggrell SA
Expert Opin Pharmacother; 2002 Apr; 3(4):455-7. PubMed ID: 11934350
[TBL] [Abstract][Full Text] [Related]
37. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Turpie AG; Eriksson BI; Lassen MR; Bauer KA
J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
[TBL] [Abstract][Full Text] [Related]
39. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
Turpie AG; Eriksson BI; Bauer KA; Lassen MR
Chest; 2003 Dec; 124(6 Suppl):371S-378S. PubMed ID: 14668420
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis].
Li H; Wang J; Xiao J; Shi Z
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Mar; 33(3):370-5. PubMed ID: 23529234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
